Advertisement


M. Catherine Pietanza, MD, on A Promising New Agent for SCLC

2015 European Cancer Congress

Advertisement

M. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell lung cancer (Abstract 7LBA).



Related Videos

Cost of Care

Martine J. Piccart-Gebhart, MD, PhD, on Reducing the Cost and Increasing Access to Cancer Drugs

Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.

Issues in Oncology
Breast Cancer

Matti S. Aapro, MD, on Geriatric Oncology: A Multidisciplinary Approach for Positive Outcomes

Matti S. Aapro, MD, of IMO Clinique de Genolier, offered a case presentation and a cross-disciplinary approach to finding the best way to effect a cure with minimal impact on quali...

Global Cancer Care

Mary K. Gospodarowicz, MD, on Challenges in Cancer Control

Mary K. Gospodarowicz, MD, of Princess Margaret Hospital, discusses the work of the Global Task Force on Radiotherapy for Cancer Control and its efforts to improve access to vital ...

Rolf A. Stahel, MD, on Results From the BELIEF Trial

Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung ...

Global Cancer Care

Milena Sant, MD, on The Latest Findings From the EUROCARE 5 Study

Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).

Advertisement

Advertisement



Advertisement